According to a recent LinkedIn post from All G, the company recently participated in the in-cosmetics Global event, marking its first time exhibiting in Europe. The post describes a high level of technical engagement with personal care partners, with discussions focused on formulation strategies and clinical validation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that it showcased recombinant lactoferrin as a component for next-generation personal care formulations. The conversations are described as grounded in preclinical and clinical data, suggesting that All G is emphasizing evidence-based differentiation rather than purely conceptual potential.
For investors, the activity at a major industry trade event may signal early commercial interest in All G’s recombinant lactoferrin platform within the personal care segment. If these technical discussions translate into development partnerships or supply agreements, they could help diversify revenue prospects and validate the technology in non-pharmaceutical applications.
The focus on clinical and preclinical data in a personal care context may also indicate that All G is targeting premium, science-led product niches, which can support higher-margin opportunities. Over time, successful adoption of recombinant lactoferrin in personal care could strengthen the company’s competitive position in bioactive ingredients and broaden its addressable market.